Scarica l'app Stockscreener
129.40
0.88%
-1.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$130.90
Aprire:
$131.18
Volume 24 ore:
91,133
Relative Volume:
0.08
Capitalizzazione di mercato:
$13.02B
Reddito:
$2.86B
Utile/perdita netta:
$478.60M
Rapporto P/E:
27.72
EPS:
4.6676
Flusso di cassa netto:
$748.70M
1 W Prestazione:
-2.12%
1M Prestazione:
+1.26%
6M Prestazione:
-6.71%
1 anno Prestazione:
+48.21%
Intervallo 1D:
$128.90
$132.92
Intervallo di 1 settimana:
$125.31
$134.20
Portata 52W:
$84.23
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
129.75 | 13.14B | 2.86B | 478.60M | 748.70M | 4.6676 |
TAK
Takeda Pharmaceutical Co Adr
|
18.68 | 57.78B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.79 | 49.30B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
10.02 | 44.03B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.13 | 34.15B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
573.41 | 24.79B | 3.18B | 1.33B | 1.04B | 27.90 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Bausch + Lomb Corporation (BLCO) and UnitedHealth (UNH) - The Globe and Mail
NBIX SEC FilingsNeurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Momentum Shift: What hedge funds are buying Neurocrine Biosciences IncMarket Activity Recap & Verified Technical Trade Signals - baoquankhu1.vn
Assessing Neurocrine Biosciences (NBIX) Valuation As Long Term Returns Outpace A Richer Earnings Multiple - Yahoo Finance
Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover - The Economic Times
RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $176 - moomoo.com
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $140 to $242 - Moomoo
Neurocrine Soleno Deal Adds Vykat XR And Alters Valuation Story - Yahoo Finance
Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology - The Chronicle-Journal
Neurocrine Biosciences (NASDAQ:NBIX) Given New $166.00 Price Target at Wedbush - MarketBeat
Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal - TechStock²
RBC Capital Adjusts Neurocrine Biosciences PT to $176 From $177, Maintains Outperform Rating - marketscreener.com
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion | Vykat XRNews and Statistics - indexbox.io
Robinhood Asset Management LLC Makes New $5.72 Million Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Weighs Soleno Deal To Broaden CNS Portfolio - simplywall.st
Neurocrine to acquire Soleno in $2.9bn transaction - Pharmaceutical Technology
Neurocrine expands portfolio with buy of Soleno Therapeutics - thepharmaletter.com
TD Cowen downgrades Soleno Therapeutics stock on Neurocrine acquisition By Investing.com - Investing.com India
TD Cowen downgrades Soleno Therapeutics stock on Neurocrine acquisition - Investing.com
Neurocrine to acquire Soleno in multi-billion dollar deal - marketscreener.com
Neurocrine Scoops Up Hunger-Drug Maker in Latest Multi-Billion-Dollar Pharma Deal - Yahoo Finance
Neurocrine to buy Soleno Therapeutics for $53/share in cash - MSN
Neurocrine-Soleno deal garners Wall Street praise — analyst applauds business development acumen - MSN
Neurocrine Agrees $2.9 Billion Soleno Deal At 34% Premium - GuruFocus
Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR - TechStock²
Neurocrine to seek Soleno (NASDAQ: SLNO) shares via tender offer - Stock Titan
Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal - Axios
Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug - MedCity News
Five More Things To Know About Neurocrine’s $2.9bn Bid For Soleno - Citeline News & Insights
This Bay Area company's stock fell to less than $1, but one decision led it to a $53-a-share acquisition - The Business Journals
Neurocrine to seek all Soleno shares in tender offer (NASDAQ: SLNO) - Stock Titan
Wedbush raises Neurocrine Bio stock price target on acquisition By Investing.com - Investing.com India
Why Soleno Therapeutics Stock Rocketed Higher on Monday - The Motley Fool
Key facts: Neurocrine buys VYKAT XR for $2.9B; adds rare‑disease asset - TradingView
Oppenheimer raises Neurocrine Biosciences price target on acquisition By Investing.com - Investing.com Canada
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout - 93.3 The Drive
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $220 From $192, Maintains Outperform Rating - marketscreener.com
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B to Expand Rare Disease Portfolio - Oncodaily
Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. - barrons.com
Baird reiterates Neurocrine Bio stock rating on acquisition potential - investing.com
Baird reiterates Neurocrine Bio stock rating on acquisition potential By Investing.com - Investing.com Australia
Cooley, Wilson Sonsini Steer Neurocrine's $2.9B Soleno Buy - Law360
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9B - National Today
American Neurocrine Biosciences acquires Soleno Therapeutics for $2.9 billion - AKM.RU
Soleno Stock Soars on $2.9 Billion Neurocrine Buyout. Its Hunger Drug Is a Different Weight-Loss Play. - Barron's
Soleno Therapeutics Soars as Neurocrine Unveils $2.9B All-Cash Buyout at $53 a Share - Yahoo Finance
Neurocrine Biosciences' (NBIX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Neurocrine Biosciences: $2.9 Billion Acquisition Of Soleno Therapeutics To Expand Rare Disease Portfolio - Pulse 2.0
Needham Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $185 - Moomoo
Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster - MarketBeat
Vykat caveat: Neurocrine’s $2.9B Soleno bid low-ball? - BioWorld News
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):